

Cyclacel Pharmaceuticals, Inc.  
Form 8-K  
August 28, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 28, 2008**

**CYCLACEL PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
**of incorporation)**

**0-50626**  
**(Commission File Number)**

**91-1707622**  
**(IRS Employer**  
**Identification No.)**

**200 Connell Drive**  
**Suite 1500**

**Berkeley Heights, NJ 07922**

**(Address of principal executive offices and zip code)**

**Registrant's telephone number, including area code: (908) 517-7330**

**(Former Name or Former Address, if Changed Since Last Report)**

**Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):**

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)**
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)**
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))**
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))**
-

**Item 8.01 Other Events.**

Attached as Exhibit 99.1 is a copy of a press release issued by Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the Company ), dated August 28, 2008, announcing recommendations of an independent data review committee (IDRC) for the Phase 2b seliciclib APPRAISE trial.

The Company will conduct a conference call to review this announcement on Thursday, August 28, 2008, at 4:30 p.m., Eastern Time.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

Number	Description
99.1	Press release, dated August 28, 2008

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**CYCLACEL PHARMACEUTICALS, INC.**

By: /s/ Paul McBarron

Name:

Paul McBarron

Title: Executive Vice President Finance and  
Chief Operating Officer

Date: August 28, 2008

---

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
<b>99.1</b>	Press Release, dated August 28, 2008